Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VRX | Valeant Pharmaceuticals International, Inc. | 1.13% | 26.96 | 14.1% | $158.64m | |
| HZNP | Horizon Therapeutics Plc | -0.33% | 77.47 | 5.6% | $140.50m | |
| ACRS | Aclaris Therapeutics, Inc. | -3.46% | 17.59 | 4.7% | $134.72m | |
| CTLT | Catalent, Inc. | -1.85% | 114.66 | 2.1% | $102.50m | |
| BHC | Bausch Health Cos., Inc. | 1.13% | 26.96 | 0.0% | $102.34m | |
| JAZZ | Jazz Pharmaceuticals Plc | 1.62% | 171.38 | 2.4% | $89.08m | |
| UTHR | United Therapeutics Corp. | -0.33% | 167.16 | 14.1% | $60.79m | |
| ACST | Acasti Pharma, Inc. | -5.13% | 0.76 | 0.2% | $59.32m | |
| ISR | IsoRay, Inc. | -2.90% | 2.18 | 2.5% | $59.10m | |
| AMRN | Amarin Corp. Plc | 15.52% | 7.57 | 1.5% | $58.69m | |
| PRGO | Perrigo Co. Plc | 2.48% | 44.37 | 6.8% | $51.91m | |
| ARGX | argenx SE | 1.54% | 315.77 | 0.0% | $51.28m | |
| GWPH | GW Pharmaceuticals Plc | -0.37% | 141.18 | 6.1% | $50.71m | |
| SAVA | Cassava Sciences, Inc. | 18.80% | 15.29 | 0.0% | $48.33m | |
| TNXP | Tonix Pharmaceuticals Holding Corp. | -0.96% | 1.02 | 0.2% | $43.95m |
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.